FDA Grants Fast Track Designation to Alzheimer's Disease Drug Candidate AZD-103/ELND005

10-Apr-2007

Transition Therapeutics Inc. announced that the United States food and Drug Administration has granted Fast Track designation to investigational drug candidate AZD-103/ELND005, being developed in collaboration with Elan Corporation, plc. for the treatment of Alzheimer's disease.

AZD-103/ELND005 is currently being evaluated in multiple Phase I clinical studies, and the companies anticipate starting Phase II clinical studies around the end of 2007.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance